HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib outside China

HUTCHMED (China) Limited announced that its subsidiary, HUTCHMED Limited, has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited to further the global development, commercialization and manufacture of fruquintinib outside of mainland China, Hong Kong and Macau.
[HUTCHMED (China) Limited]
Abstract
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News